Remdesivir has been the focus of much attention in the context of the COVID-19 pandemic. A recent examination of the WHO VigiBase® has focused on Adverse Drug Events (ADEs) amongst COVID-19 patients. 1086 ADEs were reported from the 439 individual case reports up to July 19, 2020, in the VigiBase® (1004 after elimination of duplicates). Most involved men > 45 years and were serious (82.5%). An increase in hepatic enzymes (32.1%), renal injury (14.4%), rise in creatinine levels (11.2%), and respiratory failure (6.4%) were the most frequently reported issues. Although perhaps difficult to distinguish from some features of COVID-19, the reports provide an early safety signal for the attention of clinicians. Read more here.